Mostrar el registro sencillo del ítem

Prevalence of treatment resistant depression: TRAL study sub analysis in a Mexican sample

dc.creatorVázquez Hernández, Juan Luises_ES
dc.creatorAlviso de la Serna, Luis Danieles_ES
dc.creatorCruz, Carloses_ES
dc.creatorBecerra Palars, Claudiaes_ES
dc.creatorIbarreche Beltran, Josees_ES
dc.creatorKanevsky, Gabrielaes_ES
dc.creatorCabrera, Patricia
dc.date2023
dc.date.accessioned2025-05-21T15:57:30Z
dc.date.available2025-05-21T15:57:30Z
dc.date.issued2023
dc.identifierJC126es_ES
dc.identifier.issn1028-5938
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/8363
dc.identifier.urihttps://doi.org/10.31157/an.v28i4.448
dc.descriptionIntroduction: Epidemiology and burden of disease in LatAm is often scarce in psychiatric disorders. This is particularly relevant in Treatment-Resistant Depression (TRD), a burdensome condition in a significant proportion of Major depressive disorder (MDD) patients. The Treatment Resistant Depression in America Latina (TRAL) study set out to characterize the epidemiology and burden of TRD in MDD patients. This manuscript presents this characterization for the Mexico subset based on data from the TRAL study. Methods: A sample of 697 adult patients clinically diagnosed with MDD were recruited from 14 Mexican sites. Patients with relevant psychiatric comorbidities or enrolled in a clinical trial were excluded. Outcomes were mainly patient reported outcomes and assessment scales. Results: Prevalence of TRD in Mexico was 20.7%. Current suicidality is high in TRD patients (20.8%), as well as suicide behavior disorder (12.5%). SSRIs and SNRIs were the most common medications. Results from EQ-5D, SDS and WPAI show significant limitations for TRD patients in their everyday life. Discussion: Current results are aligned with available literature on treatment and prevalence of suicidality and suicide behavior disorder. The prevalence of TRD in MDD patients is high and presents a management challenge. Conclusions: The burden of TRD in Mexico is significant, although less severe than in other LatAm countries. Public health policies should improve diagnosis and availability of novel more efficacious therapieses_ES
dc.formatPDFes_ES
dc.language.isoenges_ES
dc.publisherInstituto Nacional de Neurología y Neurocirugía, Departamento de Publicaciones Científicases_ES
dc.relation28(4):22-28
dc.rightsAcceso Cerradoes_ES
dc.titlePrevalence of treatment resistant depression: TRAL study sub analysis in a Mexican samplees_ES
dc.typeArtículoes_ES
dc.contributor.affiliationHospital Aranda de la Parra, León, Guanajuato, Mexico
dc.contributor.emailgkanevsk@its.jnj.com (Gabriela Kanevsk)
dc.relation.jnabreviadoARCH NEUROCIEN
dc.relation.journalArchivos de Neurociencias
dc.identifier.placeMéxico
dc.date.published2023
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
dc.identifier.eissn2954-4122
dc.identifier.doi10.31157/an.v28i4.448
dc.subject.kwMexico
dc.subject.kwEpidemiology
dc.subject.kwTreatment-Resistant Depressive Disorder
dc.subject.kwMajor Depressive Disorder


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem